# Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

Study · id `cardio:ct-nct01970033` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01970033](<https://clinicaltrials.gov/study/NCT01970033>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01970033

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 450 participants.

## Technical summary

Registry record NCT01970033. Randomized; quadruple masking; primary purpose treatment. Start 2012-12 (registry gives no type); primary completion 2014-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 450 participants (planned count; ClinicalTrials.gov record NCT01970033, source copy `cardio:ctgov-nct01970033-2013-10-25`, retrieved 2026-10-26)
- Start date: 2012-12 (registry gives no type) (ClinicalTrials.gov record NCT01970033, source copy `cardio:ctgov-nct01970033-2013-10-25`, retrieved 2026-10-26)
- Primary completion: 2014-01 (anticipated) (ClinicalTrials.gov record NCT01970033, source copy `cardio:ctgov-nct01970033-2013-10-25`, retrieved 2026-10-26)
- Completion: 2015-01 (anticipated) (ClinicalTrials.gov record NCT01970033, source copy `cardio:ctgov-nct01970033-2013-10-25`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT01970033, source copy `cardio:ctgov-nct01970033-2013-10-25`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01970033-2013-10-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes
- Condition: Type 2 Diabetes
- Intervention (Drug): Placebo
- Intervention (Drug): SP2086 50 mg b.i.d.
- Intervention (Drug): SP2086 100 mg q.d.
- Lead sponsor: Jiangsu HengRui Medicine Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Jiangsu HengRui Medicine Co., Ltd. (`cardio:org-jiangsu-hengrui-medicine-co-ltd`)

## Provenance

Content hash: 6fb4bb0c2439272d52ee7619ccebcc82509d05b8143be60f9451dc017e5c62d5
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
